
Patients suffering from classical melorheostosis, characterized by excessive bone growth leading to pain and deformity, have had limited treatment options. Researchers have made significant progress by creating a cellular model for studying melorheostosis. They reprogrammed patient skin cells with a specific mutation (MAP2K1) into induced pluripotent stem cells and then differentiated them into mesenchymal stem cells and osteoblasts. These modified cells exhibited elevated MEK1 activity, increased mineralization, and abundant VEGF secretion, a known stimulator of bone formation. This breakthrough suggests that targeting VEGF could hold promise as a treatment pathway for melorheostosis and potentially other rare bone diseases.
Like
Save
Share